Supernus Pharmaceuticals Inc (SUPN)
31.23
+0.77
(+2.53%)
USD |
NASDAQ |
May 07, 13:36
Supernus Pharmaceuticals Revenue (TTM): 607.52M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 607.52M |
| September 30, 2023 | 610.54M |
| June 30, 2023 | 634.01M |
| March 31, 2023 | 668.50M |
| December 31, 2022 | 667.24M |
| September 30, 2022 | 658.96M |
| June 30, 2022 | 630.07M |
| March 31, 2022 | 601.35M |
| December 31, 2021 | 579.78M |
| September 30, 2021 | 564.28M |
| June 30, 2021 | 570.95M |
| March 31, 2021 | 556.35M |
| December 31, 2020 | 520.40M |
| September 30, 2020 | 477.29M |
| June 30, 2020 | 424.29M |
| March 31, 2020 | 402.26M |
| December 31, 2019 | 392.76M |
| September 30, 2019 | 408.24M |
| June 30, 2019 | 409.10M |
| March 31, 2019 | 403.94M |
| December 31, 2018 | 408.90M |
| September 30, 2018 | 381.40M |
| June 30, 2018 | 358.80M |
| March 31, 2018 | 335.09M |
| Date | Value |
|---|---|
| December 31, 2017 | 302.24M |
| September 30, 2017 | 276.18M |
| June 30, 2017 | 252.59M |
| March 31, 2017 | 228.39M |
| December 31, 2016 | 215.00M |
| September 30, 2016 | 196.32M |
| June 30, 2016 | 178.87M |
| March 31, 2016 | 162.92M |
| December 31, 2015 | 147.46M |
| September 30, 2015 | 135.01M |
| June 30, 2015 | 118.34M |
| March 31, 2015 | 112.34M |
| December 31, 2014 | 92.68M |
| September 30, 2014 | 71.78M |
| June 30, 2014 | 50.35M |
| March 31, 2014 | 20.95M |
| December 31, 2013 | 12.02M |
| September 30, 2013 | 2.774M |
| June 30, 2013 | 1.608M |
| March 31, 2013 | 1.418M |
| December 31, 2012 | 1.479M |
| September 30, 2012 | 0.432M |
| June 30, 2012 | 0.352M |
| March 31, 2012 | 1.011M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
392.76M
Minimum
Dec 2019
668.50M
Maximum
Mar 2023
546.52M
Average
570.95M
Median
Jun 2021
Revenue (TTM) Benchmarks
| Dynavax Technologies Corp | 232.28M |
| Ligand Pharmaceuticals Inc | 131.31M |
| Pacira BioSciences Inc | 674.98M |
| Esperion Therapeutics Inc | 116.33M |
| Collegium Pharmaceutical Inc | 566.77M |